227 related articles for article (PubMed ID: 29966535)
61. Factors Associated with Ivermectin Non-Compliance and Its Potential Role in Sustaining Onchocerca volvulus Transmission in the West Region of Cameroon.
Senyonjo L; Oye J; Bakajika D; Biholong B; Tekle A; Boakye D; Schmidt E; Elhassan E
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004905. PubMed ID: 27529622
[TBL] [Abstract][Full Text] [Related]
62. Control of onchocerciasis in Africa: threshold shifts, breakpoints and rules for elimination.
Duerr HP; Raddatz G; Eichner M
Int J Parasitol; 2011 Apr; 41(5):581-9. PubMed ID: 21255577
[TBL] [Abstract][Full Text] [Related]
63. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.
Turner HC; Walker M; Churcher TS; Basáñez MG
Parasit Vectors; 2014 May; 7():241. PubMed ID: 24886747
[TBL] [Abstract][Full Text] [Related]
64. The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso.
Nikièma AS; Koala L; Sondo AK; Post RJ; Paré AB; Kafando CM; Kambiré RS; Sow B; Bougouma C; Dabiré RK; Traoré S
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009117. PubMed ID: 33647010
[TBL] [Abstract][Full Text] [Related]
65. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
Hamley JID; Blok DJ; Walker M; Milton P; Hopkins AD; Hamill LC; Downs P; de Vlas SJ; Stolk WA; Basáñez MG
Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):269-280. PubMed ID: 33515042
[TBL] [Abstract][Full Text] [Related]
66. [Control of onchocerciasis vectors in West Africa: description of the logistics adapted for a large-scale public health program].
Hougard JM; Poudiougo P; Zerbo G; Meyer R; Guillet P; Agoua H; Seketeli A; Akpoboua A; Sowah S; Samba EM
Sante; 1994; 4(6):389-98. PubMed ID: 7850190
[TBL] [Abstract][Full Text] [Related]
67. Knowledge, attitude and practice of community drug distributors' about onchocerciasis and community directed treatment with ivermectin in Quara district, North Western Ethiopia.
Weldegebreal F; Medhin G; Weldegebriel Z; Legesse M
BMC Res Notes; 2016 Apr; 9():206. PubMed ID: 27053243
[TBL] [Abstract][Full Text] [Related]
68. Onchocerciasis: shifting the target from control to elimination requires a new first-step-elimination mapping.
Rebollo MP; Zoure H; Ogoussan K; Sodahlon Y; Ottesen EA; Cantey PT
Int Health; 2018 Mar; 10(suppl_1):i14-i19. PubMed ID: 29471341
[TBL] [Abstract][Full Text] [Related]
69. APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African Programme for Onchocerciasis Control.
Homeida M; Braide E; Elhassan E; Amazigo UV; Liese B; Benton B; Noma M; Etya'alé D; Dadzie KY; Kale OO; Sékétéli A
Ann Trop Med Parasitol; 2002 Mar; 96 Suppl 1():S93-104. PubMed ID: 12081254
[TBL] [Abstract][Full Text] [Related]
70. Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.
Gebrezgabiher G; Mekonnen Z; Yewhalaw D; Hailu A
Infect Dis Poverty; 2019 Jul; 8(1):60. PubMed ID: 31269966
[TBL] [Abstract][Full Text] [Related]
71. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
[TBL] [Abstract][Full Text] [Related]
72. Genome-based tools for onchocerciasis elimination: utility of the mitochondrial genome for delineating Onchocerca volvulus transmission zones.
Crawford KE; Hedtke SM; Doyle SR; Kuesel AC; Armoo S; Osei-Atweneboana MY; Grant WN
Int J Parasitol; 2024 Mar; 54(3-4):171-183. PubMed ID: 37993016
[TBL] [Abstract][Full Text] [Related]
73. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data.
Turner HC; Walker M; Attah SK; Opoku NO; Awadzi K; Kuesel AC; Basáñez MG
Parasit Vectors; 2015 Mar; 8():167. PubMed ID: 25889256
[TBL] [Abstract][Full Text] [Related]
74. The World Bank.
Bangoura O
Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():31-3. PubMed ID: 18718152
[TBL] [Abstract][Full Text] [Related]
75. [Mectizan and onchocerciasis: 10 years of Mectizan in Africa, a partnership for prolonged success].
Pacqué M
Sante; 1998; 8(1):77-8. PubMed ID: 9592889
[No Abstract] [Full Text] [Related]
76. Vector control and entomological capacity for onchocerciasis elimination.
Tirados I; Thomsen E; Worrall E; Koala L; Melachio TT; Basáñez MG
Trends Parasitol; 2022 Jul; 38(7):591-604. PubMed ID: 35379556
[TBL] [Abstract][Full Text] [Related]
77. Community-directed vector control to supplement mass drug distribution for onchocerciasis elimination in the Madi mid-North focus of Northern Uganda.
Jacob BG; Loum D; Lakwo TL; Katholi CR; Habomugisha P; Byamukama E; Tukahebwa E; Cupp EW; Unnasch TR
PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006702. PubMed ID: 30148838
[TBL] [Abstract][Full Text] [Related]
78. The Onchocerciasis Elimination Program for the Americas: a history of partnership.
Blanks J; Richards F; Beltrán F; Collins R; Alvarez E; Zea Flores G; Bauler B; Cedillos R; Heisler M; Brandling-Bennett D; Baldwin W; Bayona M; Klein R; Jacox M
Rev Panam Salud Publica; 1998 Jun; 3(6):367-74. PubMed ID: 9734217
[TBL] [Abstract][Full Text] [Related]
79. Human Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination Programme.
Turner HC; Walker M; Lustigman S; Taylor DW; Basáñez MG
PLoS Negl Trop Dis; 2015; 9(7):e0003938. PubMed ID: 26186715
[TBL] [Abstract][Full Text] [Related]
80. Population biology of human onchocerciasis.
Basáñez MG; Boussinesq M
Philos Trans R Soc Lond B Biol Sci; 1999 Apr; 354(1384):809-26. PubMed ID: 10365406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
